AKTX

Akari Therapeutics Plc Sponsored ADR · NASDAQ

Sector Health Technology
Industry Biotechnology
Website akaritx.com
Employees(FY) 15
ISIN US00972G2075

Performance

-36.09%

-34.38%

-59.17%

-3.29%

-52.88%

YTD

-55.05%

Profile

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London, the United Kingdom.

Advanced Technical Analysis

Technical Analysis of AKTX 2024-11-20

The stock indicators reflect a bearish sentiment overall, with the Moving Average Score at 3 indicating strong bearish momentum, the Oscillators Score at 46 suggesting a neutral stance, and the Technical Score at 25 reinforcing the bearish outlook. This combination implies a lack of bullish strength and potential downward pressure on the stock.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of AKTX

Stock Rank

Recent News & Updates

2024-11-18 19:00
Akari Therapeutics Regains Full Nasdaq Compliance(Globenewswire)
2024-11-14 03:15
Akari Therapeutics Announces Successful Completion of Merger of Akari Therapeutics and Peak Bio(Globenewswire)
2024-11-07 19:00
Akari Therapeutics Announces Shareholder Approval in Connection With Peak Bio, Inc. Merger(Globenewswire)
2024-10-14 20:00
Akari Therapeutics Announces Effectiveness of Form S-4 and General Meeting Date of November 7, 2024 Related to Peak Bio Merger(Globenewswire)
2024-09-16 20:00
Rob Bazemore Appointed to the Board of Directors of Akari Therapeutics(Globenewswire)
2024-08-19 04:15
Akari Therapeutics Reports Second Quarter 2024 Financial Results and Recent Highlights(Globenewswire)
2024-08-18 20:00
Akari Therapeutics Receives Positive and Constructive Pre-IND Feedback from US FDA for PAS-nomacopan in Treatment of Geographic Atrophy(Globenewswire)
2024-06-04 20:00
Akari Therapeutics Announces Interim CEO Employment Contract Demonstrating Alignment with Shareholders(Globenewswire)
2024-06-03 20:00
Akari Therapeutics Secures $7.6 Million in Upsized Financing Round(Globenewswire)
2024-05-15 20:00
Akari Therapeutics Reports First Quarter 2024 Financial Results and Recent Highlights(Globenewswire)
2024-04-30 20:01
Samir R. Patel, M.D. Appointed Interim CEO for Akari Therapeutics(Globenewswire)
2024-04-30 20:00
Akari Therapeutics and Peak Bio Announce Portfolio Prioritization Plan for Combined Go-Forward Merger Entity(Globenewswire)
2024-04-14 20:00
Akari Therapeutics to Present PAS-Nomacopan Pre-Clinical Electroretinography (ERG) Data at ARVO 2024(Globenewswire)
2024-03-31 18:30
Akari Therapeutics Reports Full-Year 2023 Financial Results and Recent Highlights(Globenewswire)
2024-03-08 03:38
Kuehn Law Encourages VIVK, HES, SDPI, and AKTX Investors to Contact Law Firm(Globenewswire)
2024-03-04 19:00
Akari Therapeutics and Peak Bio Announce Definitive Agreement to Merge as Equals Creating an Expanded Pipeline That Features a Novel Antibody Drug Conjugate (ADC) Toolkit(Globenewswire)
2024-01-01 19:00
Akari Therapeutics Announces Existing Investors Support the Company Through a $2 Million Private Placement Financing(Globenewswire)
2023-12-13 19:00
Akari Therapeutics to Present at Biotech Showcase 2024(Globenewswire)
2023-11-30 19:00
Akari Therapeutics Appoints Experienced Life Sciences Entrepreneur Samir R. Patel, M.D. to Board of Directors(Globenewswire)
2023-11-15 19:00
Akari Therapeutics Presents Poster on Progress in Pre-Clinical Development of Long-Acting PAS-Nomacopan as a Potential Treatment for Geographic Atrophy at the 4th Annual Dry AMD Therapeutic Development Conference(Globenewswire)
2023-11-05 19:00
Akari Therapeutics to Present a Poster on Pre-Clinical Development of Long-Acting PAS-Nomacopan as a Potential Treatment for Geographic Atrophy at the 4th Annual Dry AMD Therapeutic Development Conference(Globenewswire)
2023-10-03 19:00
Presenting on the Emerging Growth Conference 63 Day 2 on October 5 Register Now(Globenewswire)
2023-10-02 19:00
Presenting on the Emerging Growth Conference 63 Day 1 on October 4 Register Now(Globenewswire)
2023-09-28 20:00
Akari Therapeutics Reports First Half 2023 Financial Results and Highlights(Globenewswire)
2023-09-26 20:00
Akari Therapeutics to Present at Emerging Growth Conference(Globenewswire)
2023-09-20 20:00
Akari Therapeutics Announces Existing Investors Support the Company Through a $2 Million Private Placement Financing, Company Also Receives $2.5 Million U.K. R&D Tax Credit(Yahoo Finance)
2023-09-18 20:00
Akari Therapeutics to Host Key Opinion Leader Webinar on Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA) and the Potential of Nomacopan to Address Significant Unmet Needs(Yahoo Finance)
2023-09-04 20:00
Akari Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement(Yahoo Finance)
2023-08-21 02:01
British pharma opens U.S. headquarters in Boston(Yahoo Finance)
2023-08-17 20:00
Akari Therapeutics Announces Establishment of Boston U.S. Headquarters Office to Support Expanding Operations and Start of Registrational Phase 3 Clinical Trials(Yahoo Finance)

Page 1 of 4

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.